U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C22H29N3O6S.C13H19NO4S
Molecular Weight 748.906
Optical Activity UNSPECIFIED
Defined Stereocenters 4 / 4
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PIVAMPICILLIN PROBENATE

SMILES

CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(O)=O.CC(C)(C)C(=O)OCOC(=O)[C@@H]2N3[C@H](SC2(C)C)[C@H](NC(=O)[C@H](N)C4=CC=CC=C4)C3=O

InChI

InChIKey=LKZFWYIOFQDUMO-GLCLSGQWSA-N
InChI=1S/C22H29N3O6S.C13H19NO4S/c1-21(2,3)20(29)31-11-30-19(28)15-22(4,5)32-18-14(17(27)25(15)18)24-16(26)13(23)12-9-7-6-8-10-12;1-3-9-14(10-4-2)19(17,18)12-7-5-11(6-8-12)13(15)16/h6-10,13-15,18H,11,23H2,1-5H3,(H,24,26);5-8H,3-4,9-10H2,1-2H3,(H,15,16)/t13-,14-,15+,18-;/m1./s1

HIDE SMILES / InChI

Molecular Formula C13H19NO4S
Molecular Weight 285.359
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C22H29N3O6S
Molecular Weight 463.547
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 4 / 4
E/Z Centers 0
Optical Activity UNSPECIFIED

Ampicillin is a penicillin beta-lactam antibiotic. The following gram-negative and gram-positive bacteria have been shown in in vitro studies to be susceptible to ampicillin: Hemolytic and nonhemolytic streptococci, Streptococcus pneumoniae, Nonpenicillinase-producing staphylococci, Clostridium spp., B. anthracis, Listeria monocytogenes, most strains of enterococci, H. influenzae, N. gonorrhoeae, N. meningitidis, Proteus mirabilis, many strains of Salmonella, Shigella, and E. coli. Ampicillin is indicated in the treatment of bacterial meningitis, septicemia, endocarditis, urinary tract, gastrointestinal, respiratory tract infections caused by susceptible strains of the designated organisms.

CNS Activity

Curator's Comment: Ampicillin penetration into the cerebrospinal fluid and brain occurs only when the meninges are inflamed.

Originator

Sources: DOYLE, F.P., NAYLER, J.H.C. & SMITH, H. (1961). British Patent Specification No. 873049.
Curator's Comment: reference retrieved from https://www.ncbi.nlm.nih.gov/pubmed/13859205

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
AMPICILLIN SODIUM

Approved Use

Ampicillin is indicated in the treatment of bacterial meningitis, septicemia, endocarditis, urinary tract, gastrointestinal, respiratory tracti nfections caused by susceptible strains of bacteria (Hemolytic and nonhemolytic streptococci, Streptococcus pneumoniae, Nonpenicillinase-producing staphylococci, Clostridium spp., B. anthracis, Listeria monocytogenes, most strains of enterococci, H. influenzae, N. gonorrhoeae, N. meningitidis, Proteus mirabilis, many strains of Salmonella, Shigella, and E. coli.)
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
15.04 μg/mL
1500 mg single, oral
dose: 1500 mg
route of administration: Oral
experiment type: SINGLE
co-administered: PROBENECID
AMPICILLIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
129.5 μg/mL
2000 mg single, intravenous
dose: 2000 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered: SULBACTAM
AMPICILLIN plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
58.74 μg × h/mL
1500 mg single, oral
dose: 1500 mg
route of administration: Oral
experiment type: SINGLE
co-administered: PROBENECID
AMPICILLIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
1.82 h
1500 mg single, oral
dose: 1500 mg
route of administration: Oral
experiment type: SINGLE
co-administered: PROBENECID
AMPICILLIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
1 h
2000 mg single, intravenous
dose: 2000 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered: SULBACTAM
AMPICILLIN plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
72%
AMPICILLIN serum
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
650 mg 3 times / day multiple, intravenous
Studied dose
Dose: 650 mg, 3 times / day
Route: intravenous
Route: multiple
Dose: 650 mg, 3 times / day
Sources:
unhealthy, 11 to 18 months
Health Status: unhealthy
Age Group: 11 to 18 months
Sex: M+F
Sources:
Disc. AE: Skin rash...
AEs leading to
discontinuation/dose reduction:
Skin rash (25%)
Sources:
5 g 3 times / day multiple, intravenous
Highest studied dose
Dose: 5 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 5 g, 3 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
0.5 g 1 times / day single, intramuscular
Recommended
Dose: 0.5 g, 1 times / day
Route: intramuscular
Route: single
Dose: 0.5 g, 1 times / day
Sources:
healthy, adult
Health Status: healthy
Age Group: adult
Sex: M
Sources:
Other AEs: Injection site pain...
1 g 1 times / day single, intramuscular
Studied dose
Dose: 1 g, 1 times / day
Route: intramuscular
Route: single
Dose: 1 g, 1 times / day
Sources:
healthy, adult
Health Status: healthy
Age Group: adult
Sex: M
Sources:
Other AEs: Injection site pain, Creatine phosphokinase increased...
Other AEs:
Injection site pain (grade 3-4, 100%)
Creatine phosphokinase increased (100%)
Sources:
2 g 1 times / day single, intramuscular
Studied dose
Dose: 2 g, 1 times / day
Route: intramuscular
Route: single
Dose: 2 g, 1 times / day
Sources:
unhealthy, mean age 25.8 years
Health Status: unhealthy
Age Group: mean age 25.8 years
Sex: M+F
Sources:
Other AEs: Injection site pain, Rash...
Other AEs:
Injection site pain (1%)
Rash (1%)
Diarrhea (5%)
Fatigue (3%)
Chills (1%)
Headache (1%)
AST increased (3%)
Bilirubin increased (1%)
Creatinine increased (1%)
Sources:
2 g 3 times / day multiple, intravenous
Studied dose
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, mean age 27.1 years
Health Status: unhealthy
Age Group: mean age 27.1 years
Sex: F
Sources:
Other AEs: Chest pain, Flatulence...
Other AEs:
Chest pain (5%)
Flatulence (5%)
Diarrhea (10%)
Injection site pain (5%)
Sources:
2 g 3 times / day multiple, intravenous
Studied dose
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, mean age 27.4 years
Health Status: unhealthy
Age Group: mean age 27.4 years
Sex: M+F
Sources:
Other AEs: Injection site pain, Phlebitis...
Other AEs:
Injection site pain (0.8%)
Phlebitis (5.3%)
Chest pain (0.8%)
Diarrhea (6.8%)
Vomiting (0.8%)
Retention of urine (0.8%)
Rash (0.8%)
Epistaxis (0.8%)
Edema (0.8%)
Sources:
2 g 3 times / day multiple, intravenous
Studied dose
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, mean age 60.1 years
Health Status: unhealthy
Age Group: mean age 60.1 years
Sex: M+F
Sources:
Other AEs: Thrombophlebitis, Nausea...
Other AEs:
Thrombophlebitis (6.7%)
Nausea (6.7%)
Diarrhea (6.7%)
Rash (6.7%)
Blood eosinophils increased (6.7%)
AST increased (6.7%)
ALT increased (13.3%)
GGT increased (13.3%)
Alkaline phosphatase increased (6.7%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Skin rash 25%
Disc. AE
650 mg 3 times / day multiple, intravenous
Studied dose
Dose: 650 mg, 3 times / day
Route: intravenous
Route: multiple
Dose: 650 mg, 3 times / day
Sources:
unhealthy, 11 to 18 months
Health Status: unhealthy
Age Group: 11 to 18 months
Sex: M+F
Sources:
Injection site pain
0.5 g 1 times / day single, intramuscular
Recommended
Dose: 0.5 g, 1 times / day
Route: intramuscular
Route: single
Dose: 0.5 g, 1 times / day
Sources:
healthy, adult
Health Status: healthy
Age Group: adult
Sex: M
Sources:
Creatine phosphokinase increased 100%
1 g 1 times / day single, intramuscular
Studied dose
Dose: 1 g, 1 times / day
Route: intramuscular
Route: single
Dose: 1 g, 1 times / day
Sources:
healthy, adult
Health Status: healthy
Age Group: adult
Sex: M
Sources:
Injection site pain grade 3-4, 100%
1 g 1 times / day single, intramuscular
Studied dose
Dose: 1 g, 1 times / day
Route: intramuscular
Route: single
Dose: 1 g, 1 times / day
Sources:
healthy, adult
Health Status: healthy
Age Group: adult
Sex: M
Sources:
Bilirubin increased 1%
2 g 1 times / day single, intramuscular
Studied dose
Dose: 2 g, 1 times / day
Route: intramuscular
Route: single
Dose: 2 g, 1 times / day
Sources:
unhealthy, mean age 25.8 years
Health Status: unhealthy
Age Group: mean age 25.8 years
Sex: M+F
Sources:
Chills 1%
2 g 1 times / day single, intramuscular
Studied dose
Dose: 2 g, 1 times / day
Route: intramuscular
Route: single
Dose: 2 g, 1 times / day
Sources:
unhealthy, mean age 25.8 years
Health Status: unhealthy
Age Group: mean age 25.8 years
Sex: M+F
Sources:
Creatinine increased 1%
2 g 1 times / day single, intramuscular
Studied dose
Dose: 2 g, 1 times / day
Route: intramuscular
Route: single
Dose: 2 g, 1 times / day
Sources:
unhealthy, mean age 25.8 years
Health Status: unhealthy
Age Group: mean age 25.8 years
Sex: M+F
Sources:
Headache 1%
2 g 1 times / day single, intramuscular
Studied dose
Dose: 2 g, 1 times / day
Route: intramuscular
Route: single
Dose: 2 g, 1 times / day
Sources:
unhealthy, mean age 25.8 years
Health Status: unhealthy
Age Group: mean age 25.8 years
Sex: M+F
Sources:
Injection site pain 1%
2 g 1 times / day single, intramuscular
Studied dose
Dose: 2 g, 1 times / day
Route: intramuscular
Route: single
Dose: 2 g, 1 times / day
Sources:
unhealthy, mean age 25.8 years
Health Status: unhealthy
Age Group: mean age 25.8 years
Sex: M+F
Sources:
Rash 1%
2 g 1 times / day single, intramuscular
Studied dose
Dose: 2 g, 1 times / day
Route: intramuscular
Route: single
Dose: 2 g, 1 times / day
Sources:
unhealthy, mean age 25.8 years
Health Status: unhealthy
Age Group: mean age 25.8 years
Sex: M+F
Sources:
AST increased 3%
2 g 1 times / day single, intramuscular
Studied dose
Dose: 2 g, 1 times / day
Route: intramuscular
Route: single
Dose: 2 g, 1 times / day
Sources:
unhealthy, mean age 25.8 years
Health Status: unhealthy
Age Group: mean age 25.8 years
Sex: M+F
Sources:
Fatigue 3%
2 g 1 times / day single, intramuscular
Studied dose
Dose: 2 g, 1 times / day
Route: intramuscular
Route: single
Dose: 2 g, 1 times / day
Sources:
unhealthy, mean age 25.8 years
Health Status: unhealthy
Age Group: mean age 25.8 years
Sex: M+F
Sources:
Diarrhea 5%
2 g 1 times / day single, intramuscular
Studied dose
Dose: 2 g, 1 times / day
Route: intramuscular
Route: single
Dose: 2 g, 1 times / day
Sources:
unhealthy, mean age 25.8 years
Health Status: unhealthy
Age Group: mean age 25.8 years
Sex: M+F
Sources:
Diarrhea 10%
2 g 3 times / day multiple, intravenous
Studied dose
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, mean age 27.1 years
Health Status: unhealthy
Age Group: mean age 27.1 years
Sex: F
Sources:
Chest pain 5%
2 g 3 times / day multiple, intravenous
Studied dose
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, mean age 27.1 years
Health Status: unhealthy
Age Group: mean age 27.1 years
Sex: F
Sources:
Flatulence 5%
2 g 3 times / day multiple, intravenous
Studied dose
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, mean age 27.1 years
Health Status: unhealthy
Age Group: mean age 27.1 years
Sex: F
Sources:
Injection site pain 5%
2 g 3 times / day multiple, intravenous
Studied dose
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, mean age 27.1 years
Health Status: unhealthy
Age Group: mean age 27.1 years
Sex: F
Sources:
Chest pain 0.8%
2 g 3 times / day multiple, intravenous
Studied dose
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, mean age 27.4 years
Health Status: unhealthy
Age Group: mean age 27.4 years
Sex: M+F
Sources:
Edema 0.8%
2 g 3 times / day multiple, intravenous
Studied dose
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, mean age 27.4 years
Health Status: unhealthy
Age Group: mean age 27.4 years
Sex: M+F
Sources:
Epistaxis 0.8%
2 g 3 times / day multiple, intravenous
Studied dose
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, mean age 27.4 years
Health Status: unhealthy
Age Group: mean age 27.4 years
Sex: M+F
Sources:
Injection site pain 0.8%
2 g 3 times / day multiple, intravenous
Studied dose
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, mean age 27.4 years
Health Status: unhealthy
Age Group: mean age 27.4 years
Sex: M+F
Sources:
Rash 0.8%
2 g 3 times / day multiple, intravenous
Studied dose
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, mean age 27.4 years
Health Status: unhealthy
Age Group: mean age 27.4 years
Sex: M+F
Sources:
Retention of urine 0.8%
2 g 3 times / day multiple, intravenous
Studied dose
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, mean age 27.4 years
Health Status: unhealthy
Age Group: mean age 27.4 years
Sex: M+F
Sources:
Vomiting 0.8%
2 g 3 times / day multiple, intravenous
Studied dose
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, mean age 27.4 years
Health Status: unhealthy
Age Group: mean age 27.4 years
Sex: M+F
Sources:
Phlebitis 5.3%
2 g 3 times / day multiple, intravenous
Studied dose
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, mean age 27.4 years
Health Status: unhealthy
Age Group: mean age 27.4 years
Sex: M+F
Sources:
Diarrhea 6.8%
2 g 3 times / day multiple, intravenous
Studied dose
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, mean age 27.4 years
Health Status: unhealthy
Age Group: mean age 27.4 years
Sex: M+F
Sources:
ALT increased 13.3%
2 g 3 times / day multiple, intravenous
Studied dose
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, mean age 60.1 years
Health Status: unhealthy
Age Group: mean age 60.1 years
Sex: M+F
Sources:
GGT increased 13.3%
2 g 3 times / day multiple, intravenous
Studied dose
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, mean age 60.1 years
Health Status: unhealthy
Age Group: mean age 60.1 years
Sex: M+F
Sources:
AST increased 6.7%
2 g 3 times / day multiple, intravenous
Studied dose
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, mean age 60.1 years
Health Status: unhealthy
Age Group: mean age 60.1 years
Sex: M+F
Sources:
Alkaline phosphatase increased 6.7%
2 g 3 times / day multiple, intravenous
Studied dose
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, mean age 60.1 years
Health Status: unhealthy
Age Group: mean age 60.1 years
Sex: M+F
Sources:
Blood eosinophils increased 6.7%
2 g 3 times / day multiple, intravenous
Studied dose
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, mean age 60.1 years
Health Status: unhealthy
Age Group: mean age 60.1 years
Sex: M+F
Sources:
Diarrhea 6.7%
2 g 3 times / day multiple, intravenous
Studied dose
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, mean age 60.1 years
Health Status: unhealthy
Age Group: mean age 60.1 years
Sex: M+F
Sources:
Nausea 6.7%
2 g 3 times / day multiple, intravenous
Studied dose
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, mean age 60.1 years
Health Status: unhealthy
Age Group: mean age 60.1 years
Sex: M+F
Sources:
Rash 6.7%
2 g 3 times / day multiple, intravenous
Studied dose
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, mean age 60.1 years
Health Status: unhealthy
Age Group: mean age 60.1 years
Sex: M+F
Sources:
Thrombophlebitis 6.7%
2 g 3 times / day multiple, intravenous
Studied dose
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, mean age 60.1 years
Health Status: unhealthy
Age Group: mean age 60.1 years
Sex: M+F
Sources:
PubMed

PubMed

TitleDatePubMed
Highly efficient synthesis of ampicillin in an "aqueous solution-precipitate" system: repetitive addition of substrates in a semicontinuous process.
2001-06-05
Clinical prevalence, antimicrobial susceptibility, and geographic resistance patterns of enterococci: results from the SENTRY Antimicrobial Surveillance Program, 1997-1999.
2001-05-15
Ampicillin-resistant Escherichia coli in gestational pyelonephritis: increased occurrence and association with the colonization factor Dr adhesin.
2001-05-15
Treatment of foodborne listeriosis.
2001-05-15
Ureidopenicillins and risk of Clostridium difficile infection.
2001-05
Carriage of antibiotic-resistant bacteria by healthy children.
2001-05
Antibiotic resistance and antibiotic sensitivity based treatment in Helicobacter pylori infection: advantages and outcome.
2001-05
Study of the in vitro activity of amoxicillin/clavulanic acid and other beta-lactam antibiotics against Escherichia coli isolated from urine specimens.
2001-04-20
Sepsis and multiple brain abscesses caused by Salmonella paratyphi B in an infant: successful treatment with sulbactam-ampicillin and surgical drainage.
2001-04-12
Emergence of vancomycin-resistant enterococci.
2001-04-11
Simultaneous determination of five beta-lactam antibiotics in bovine milk using liquid chromatography coupled with electrospray ionization tandem mass spectrometry.
2001-04-01
Enterobacter spp. infections complicating the course of HIV disease.
2001-04
Prevalence of penicillin-resistant Streptococcus pneumoniae in Kuwait.
2001-04
Antimicrobial resistance of Streptococcus pneumoniae at a university hospital in Saudi Arabia.
2001-04
Antibiotic use and development of resistance in blood culture isolates: 8 years of experience from a cancer referral center.
2001-04
Infant botulism: case reports and review.
2001-04
The isolation and characterization of Campylobacter jejuni subsp. jejuni from domestic geese (Anser anser).
2001-04
Antibiotic resistance among Listeria, including Listeria monocytogenes, in retail foods.
2001-04
[Clinical characteristics of beta-lactamase negative ampicillin resistant Haemophilus influenzae (BLNAR) in respiratory tract].
2001-04
[Combination therapy against vancomycin-resistant enterococci].
2001-04
[Beta-lactamase negative ampicillin-resistant Haemophilus influenzae(BLNAR)].
2001-04
[Beta-lactam and macrolide resistance in Streptococcus pneumoniae].
2001-04
[Vancomycin-resistant enterococci(VRE)].
2001-04
Use of antibiotics to treat bacteriuria of pregnancy in the Nordic countries. Which antibiotics are appropriate to treat bacteriuria of pregnancy?
2001-04
Expanding the genetic code: selection of efficient suppressors of four-base codons and identification of "shifty" four-base codons with a library approach in Escherichia coli.
2001-03-30
[Prevalence of Moraxella catarrhalis colonization in asymptomatic carriers under 6 years of age].
2001-03-29
Antimicrobial susceptibilities of Erysipelothrix rhusiopathiae isolated from pigs with swine erysipelas in Japan, 1988-1998.
2001-03
Standard case management of pneumonia in hospitalized children in Uruguay, 1997 to 1998.
2001-03
Antibiotic-resistant bacteria in pediatric chronic sinusitis.
2001-03
Neonatal sepsis and mortality in a regional hospital in Trinidad: aetiology and risk factors.
2001-03
Antimicrobial resistance of Enterococci in Lebanon.
2001-03
Screening method for identification of beta-lactams in bovine urine by use of liquid chromatography and a microbial inhibition test.
2001-03
Fulminant pneumonia due to Aeromonas hydrophila in a man with chronic renal failure and liver cirrhosis.
2001-02
Serogroups and antimicrobial susceptibility of non-typhoidal salmonellas in children.
2001-02
Enterococcus faecalis resistant to vancomycin and teicoplanin (VanA phenotype) isolated from a bone marrow transplanted patient in Brazil.
2001-02
Multicenter evaluation of resistance patterns of Klebsiella pneumoniae, Escherichia coli, Salmonella spp and Shigella spp isolated from clinical specimens in Brazil: RESISTNET Surveillance Program.
2001-02
Spectrophotometric determination of ampicillin, dicluxacillin, flucloxacillin and amoxicillin antibiotic drugs: ion-pair formation with molybdenum and thiocyanate.
2001-02
Novel quantitative assays for estimating the antimicrobial activity of fresh garlic juice.
2001-02
Illegal abortions in Addis Ababa, Ethiopia.
2001-01
A simple classification method for residual antibiotics using E. coli cells transformed by the calcium chloride method and drug resistance plasmid DNA.
2001
Molecular epidemiology and mutations at gyrA and parC genes of ciprofloxacin-resistant Escherichia coli isolates from a Taiwan medical center.
2001
In vitro activity of 19 antimicrobial agents against enterococci from healthy subjects and hospitalized patients and use of an ace gene probe from Enterococcus faecalis for species identification.
2001
A multicenter study of the antimicrobial susceptibility of Haemophilus influenzae, Streptococcus pneumoniae, and Moraxella catarrhalis isolated from patients with community-acquired lower respiratory tract infections in 1999 in Portugal.
2001
Variation in clonality and antibiotic-resistance genes among multiresistant Salmonella enterica serotype typhimurium phage-type U302 (MR U302) from humans, animals, and foods.
2001
Ampicillin-resistant enterococci in a Swedish university hospital: nosocomial spread and risk factors for infection.
2001
Superantigen antagonist peptides.
2001
Antibiotic susceptibility, serum response and surface properties of Klebsiella species.
2001
Survey of transcripts in the adult Drosophila brain.
2001
[Achromobacter xylosoxidans bacteremia in a patient with community-acquired pneumonia].
2001
Acute interstitial nephritis following ampicillin hypersensitivity.
1975-01-18
Patents

Patents

Sample Use Guides

In Vivo Use Guide
Ampicillin Dosage and Administration This insert is for a Pharmacy Bulk Package and is intended for preparing IV admixtures only. Dosage recommendations for intramuscular or direct intravenous injection are for informational purposes only. Infections of the respiratory tract and soft tissues. Patients weighing 40 kg (88 lbs) or more: 250 to 500 mg every 6 hours. Patients weighing less than 40 kg (88 lbs): 25 to 50 mg/kg/day in equally divided doses at 6- to 8- hour intervals. Infections of the gastrointestinal and genitourinary tracts (including those caused by Neisseria gonorrhoeae in females). Patients weighing 40 kg (88 lbs) or more: 500 mg every 6 hours. Patients weighing less than 40 kg (88 lbs): 50 mg/kg/day in equally divided doses at 6- to 8- hour intervals. In the treatment of chronic urinary tract and intestinal infections, frequent bacteriological and clinical appraisal is necessary. Smaller doses than those recommended above should not be used. Higher doses should be used for stubborn or severe infections. In stubborn infections, therapy may be required for several weeks. It may be necessary to continue clinical and/or bacteriological follow-up for several months after cessation of therapy. Urethritis in males due to N. gonorrhoeae. Adults – Two doses of 500 mg each at an interval of 8 to 12 hours. Treatment may be repeated if necessary or extended if required. In the treatment of complications of gonorrheal urethritis, such as prostatitis and epididymitis, prolonged and intensive therapy is recommended. Cases of gonorrhea with a suspected primary lesion of syphilis should have darkfield examinations before receiving treatment. In all other cases where concomitant syphilis is suspected, monthly serological tests should be made for a minimum of four months. The doses for the preceding infections may be given by either the intramuscular or intravenous route. A change to oral Ampicillin may be made when appropriate. Bacterial Meningitis Adults and children – 150 to 200 mg/kg/day in equally divided doses every 3 to 4 hours. (Treatment may be initiated with intravenous drip therapy and continued with intramuscular injections.) The doses for other infections may be given by either the intravenous or intramuscular route. Septicemia Adults and children – 150 to 200 mg/kg/day. Start with intravenous administration for at least three days and continue with the intramuscular route every 3 to 4 hours. Treatment of all infections should be continued for a minimum of 48 to 72 hours beyond the time that the patient becomes asymptomatic or evidence of bacterial eradication has been obtained. A minimum of 10-days treatment is recommended for any infection caused by Group A beta-hemolytic streptococci to help prevent the occurrence of acute rheumatic fever or acute glomerulonephritis.
Route of Administration: Other
Ampicillin was tested in vitro for antibacterial activity against 673 clinical isolates of Gram-negative bacilli and Streptococcus faecalis. Taking the group of 673 isolates tested as a whole, 448 (67 %) were inhibited by ampicillin at a concentration of 5 ug/ml.
Substance Class Chemical
Created
by admin
on Mon Mar 31 18:04:08 GMT 2025
Edited
by admin
on Mon Mar 31 18:04:08 GMT 2025
Record UNII
M3MYK6R22U
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PIVAMPICILLIN PROBENATE
USAN  
USAN  
Official Name English
PIVAMPICILLIN PROBENATE [USAN]
Preferred Name English
Classification Tree Code System Code
NCI_THESAURUS C1500
Created by admin on Mon Mar 31 18:04:08 GMT 2025 , Edited by admin on Mon Mar 31 18:04:08 GMT 2025
Code System Code Type Description
CAS
42190-91-0
Created by admin on Mon Mar 31 18:04:08 GMT 2025 , Edited by admin on Mon Mar 31 18:04:08 GMT 2025
PRIMARY
MESH
C012649
Created by admin on Mon Mar 31 18:04:08 GMT 2025 , Edited by admin on Mon Mar 31 18:04:08 GMT 2025
PRIMARY
FDA UNII
M3MYK6R22U
Created by admin on Mon Mar 31 18:04:08 GMT 2025 , Edited by admin on Mon Mar 31 18:04:08 GMT 2025
PRIMARY
EPA CompTox
DTXSID00195021
Created by admin on Mon Mar 31 18:04:08 GMT 2025 , Edited by admin on Mon Mar 31 18:04:08 GMT 2025
PRIMARY
SMS_ID
300000055007
Created by admin on Mon Mar 31 18:04:08 GMT 2025 , Edited by admin on Mon Mar 31 18:04:08 GMT 2025
PRIMARY
PUBCHEM
65322
Created by admin on Mon Mar 31 18:04:08 GMT 2025 , Edited by admin on Mon Mar 31 18:04:08 GMT 2025
PRIMARY
NCI_THESAURUS
C66441
Created by admin on Mon Mar 31 18:04:08 GMT 2025 , Edited by admin on Mon Mar 31 18:04:08 GMT 2025
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY